Patents Assigned to Inserm
-
Patent number: 12048761Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion. In particular, the present invention relates to a method of treating retinal capillary non-perfusion in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a ROCK inhibitor.Type: GrantFiled: October 12, 2016Date of Patent: July 30, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ PARIS DESCARTES, UNIVERSITÉ PARIS DIDEROT—PARIS 7, FONDATION ASILE DES AVEUGLES, SORBONNE UNIVERSITÉInventors: Francine Behar-Cohen, Patricia Crisanti-Lassiaz
-
Patent number: 12048693Abstract: The present invention relates to a compound of general formula (I), wherein R1 is OCH2CH2OCH3 or OCH3, R?1 is H or OH, R2 is Cl, F, Br or I, with the proviso that when: R1 is OCH2CH2OCH3 then R?1 is H, R1 is OCH3 then R?1 is OH, its pharmaceutically acceptable salts and/or optical isomers, tautomers, solvates or isotopic variations thereof. The invention also relates to said compounds for use in the treatment of cancer, namely solid tumor cancer, and preferably those selected from melanoma, colon, lung, pancreas, kidney, Merkel carcinoma, squamous cell carcinoma, prostate, breast and bladder. The invention also relates to a pharmaceutical composition comprising said compounds.Type: GrantFiled: January 4, 2019Date of Patent: July 30, 2024Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ CÔTE D'AZURInventors: Thierry Passeron, Rachid Benhida, Pascal Dao, Gian Marco De Donatis, Anthony Martin
-
Patent number: 12049480Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.Type: GrantFiled: November 22, 2023Date of Patent: July 30, 2024Assignees: Institut National De La Sante Et De La Recherche Medicale (INSERM) Paris, FRANCE, Centre National De La Recherche Scientifique (CNRS) Paris, FRANCEInventors: Théophile Ohlmann, Philippe Mangeot, Emiliano Ricci
-
METHODS FOR DETECTING INACTIVATION OF THE HOMOLOGOUS RECOMBINATION PATHWAY (BRCA1/2) IN HUMAN TUMORS
Publication number: 20240247318Abstract: The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.Type: ApplicationFiled: February 14, 2024Publication date: July 25, 2024Applicants: Institute Curie, INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Marc-Henri Stern, Elodie Manie, Tatiana Popova -
Patent number: 12045980Abstract: A Method for generating a biomarker includes acquiring an image using an MRI system; processing the MRI image to generate a three-dimensional image of the lung; generating a first function corresponding to the distribution of the different signal intensity values; automatically calculating a filtering threshold of the first function from a second signal intensity value distribution function; segmenting a lung volume comprising: a main volume; a filtered volume of a volume of voxels quantified by the first function and filtered by at least the calculated filtering threshold, normalizing the values of the three-dimensional image of the lung volume; generating a biomarker indicating a normalized segmented volume ratio.Type: GrantFiled: June 3, 2020Date of Patent: July 23, 2024Assignees: UNIVERSITE DE BORDEAUX, CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE—INSERMInventors: Gael Dournes, Ilyes Benlala, François Laurent, Patrick Berger
-
Publication number: 20240240254Abstract: Methods of diagnosing subclinical rejection, based on the level, amount or concentration of two genes, TCL1A and AKR1C3, whether independently from each other or in combination. When in combination, the level, amount or concentration of the two genes can further be combined with clinical parameters in the form of a composite score. Also, methods for treating subclinical rejection in a subject if/when the subject was diagnosed with subclinical rejection using the method of the invention; as well as a computer system and a kit-of-parts for implementing the method of diagnosing subclinical rejection.Type: ApplicationFiled: May 25, 2022Publication date: July 18, 2024Applicants: CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES, NANTES UNIVERSITÉ, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)Inventors: Sophie BROUARD, Richard DANGER, Magali GIRAL
-
Patent number: 12036237Abstract: The present invention relates to a novel pharmaceutical use of bromide, i.e. the treatment of autism spectral disorder (ASD).Type: GrantFiled: April 20, 2023Date of Patent: July 16, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, CNRS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE STRASBOURGInventors: Sébastien Roux, Thierry Plouvier, Julie Le Merrer, Jérôme Becker
-
Publication number: 20240228546Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.Type: ApplicationFiled: April 3, 2023Publication date: July 11, 2024Applicants: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1Inventors: Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
-
Publication number: 20240228659Abstract: A combination of retinoic acid, an anti-O-acetylated disialoganglioside (OAcGD2) compound and an anti-PD1/PD-L1 compound for treating a cancer, particularly neuroblastoma, in a subject in need thereof. The inventors focused on immunotherapeutic strategies targeting OAcGD2, believing they could address critical neuropathic pain side effects associated with anti-GD2 mAb infusions. They reported mAb 8B6 targeting OAcGD2 displays antitumor activity in NB tumor models, with induction of ADCC similarly to anti-GD2 mAbs. From this, the inventors interrogated whether 13-cis-RA and retinoic acid generally, may augment anti-NB efficiency of mAb 8B6 therapy. They found cooperative interaction of 13-cis-RA and mAb 8B6 treatment in inhibiting the NB growth in vivo. However, this combination regimen also coordinates PD-1/PD-L1 upregulation, which hinders a long-term activation of NK cells and allows tumor cell to relapse.Type: ApplicationFiled: April 13, 2022Publication date: July 11, 2024Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), NANTES UNIVERSITÉ, OGD2 PHARMAInventors: Stéphane BIRKLE, Meriem BAHRI, Sophie FOUGERAY, Jean-Marc LE DOUSSAL, Emilie MADURA
-
Patent number: 12023420Abstract: The present invention relates to a vascular stent, deployed or non-deployed, the surface of which is coated by a film comprising at least one protein, to a process for coating of the surface of a vascular stent with a film comprising at least one protein and to a device for carrying out the process according to the invention.Type: GrantFiled: June 5, 2019Date of Patent: July 2, 2024Assignees: UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM-INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALEInventors: Christophe Cognard, Olivier Eichwald, Cédric Garcia, Nofel Merbahi, Bernard Payrastre, Pierre Sie, Aurélie Tokarski, Ivan Vukasinovic, Mohammed Yousfi
-
Publication number: 20240201185Abstract: The present invention is directed to methods of diagnosis and treatment of autoimmune, chronic inflammatory and lymphoproliferative diseases based on the identification of a population of pathogenic B and/or T cells showing a specific phenotype. These cells may be identified by their specific pattern of expression of marker proteins.Type: ApplicationFiled: April 21, 2022Publication date: June 20, 2024Applicants: SORBONNE UNIVERSITE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE – HOPITAUX DE PARISInventors: Cindy MARQUES, Paul REGNIER, David SAADOUN
-
Patent number: 12011466Abstract: The invention relates to the field of modified Escherichia coli strain Nissle 1917 (EcN) and its use for treating gastro-intestinal disorders. The invention is based on the study of the mechanisms implicated in the probiotic properties of the Escherichia coli strain Nissle 1917 (EcN). This study has allowed the inventors to decouple the probiotic activity of EcN from its genotoxic activity by demonstrating that EcN ClbP protein, the enzyme that activates the genotoxin colibactin, is also required for the siderophore-microcins activity of probiotic EcN, but interestingly, not its enzymatic domain that cleaves precolibactin to form active colibactin.Type: GrantFiled: July 7, 2020Date of Patent: June 18, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PAUL SABATIER TOULOUSE III, ECOLE NATIONALE VÉTÉRINAIRE DE TOULOUSE, INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Eric Oswald, Jean-Philippe Nougayrede, Clémence Massip, Patricia Martin, Priscilla Branchu
-
Publication number: 20240190993Abstract: The treatment of cancer and particularly the neuroblastoma, and a combination of an anti-O-acetylated disialoganglioside (OAcGD2) compound and an anti-SIRP-alpha/CD47 compound for treating a cancer in a subject in need thereof. The inventors hypothesized that CD47 expression would interfere with the contribution of macrophage to the therapeutic effect of anti-OAcGD2 mAbs. They found that NB cells up-regulate CD47 expression upon 8B6 mAb immunotherapy in vivo, allowing them to escape mAb 8B6-mediated ADP. Next, they demonstrate that an anti-SIRP? antibody that blocks the binding of CD47 to SIRP? enables macrophages to phagocyte anti-OAcGD2-opsonised CD47-expressing NB cells in vitro. As a result, the combination of CD47 blocking with the targeting of OAcGD2-positive NB cells greatly reduces tumor growth in syngeneic mice.Type: ApplicationFiled: April 13, 2022Publication date: June 13, 2024Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), OGD2 PHARMA, NANTES UNIVERSITÉInventors: Stéphane BIRKLE, Sarah VERMEULEN, Sophie FOUGERAY, Meriem BAHRI, Emilie MADURA, Jean-Marc LE DOUSSAL
-
Publication number: 20240181075Abstract: The present invention relates to an antibody-drug conjugate comprising a monoclonal antibody or an antigen-binding fragment thereof wherein the monoclonal antibody or the antigen-binding fragment thereof binds to Nectin-4 and wherein the drug is an amatoxin, particularly ?-amanitin.Type: ApplicationFiled: March 31, 2022Publication date: June 6, 2024Applicants: EMERGENCE THERAPEUTICS AG, UNIVERSITE D’AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE – CNRSInventors: Jack ELANDS, Florence LHOSPPICE, Xavier PRÉVILLE, Daniel OLIVE, Marc LOPEZ
-
Publication number: 20240183824Abstract: An ultrasound probe includes a connector and a probe head that includes a mount located in a tip part of the probe head, various linear matrices of transducers that emit acoustic waves with a given central wavelength and detect backscattered acoustic waves. The linear matrices are electrically connected to the connector, wherein each linear matrix from the linear matrices of transducers includes a first side along a first direction and a second side along a second direction. The second side is smaller than the first side. The linear matrices are fixed to the mount and juxtaposed on the mount with the first sides adjacent. Each linear matrix from the linear matrices of transducers is covered with a single cylindrical acoustic lens that focuses the acoustic waves emitted by the linear matrix. Each cylindrical acoustic lens includes a cylindrical axis substantially parallel to the first direction.Type: ApplicationFiled: December 21, 2021Publication date: June 6, 2024Applicants: ICONEUS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Centre National de la Recherche Scientifique, ECOLE SUPÉRIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARISInventors: Bruno-Felix Osmanski, Thomas Deffieux, Mathieu Pernot, Adrien Bertolo, Charlie Demene
-
Publication number: 20240180930Abstract: A method of treatment or prevention of myeloproliferative disorders and other hematopoietic malignancies is described. A carbonic Anhydrase 1 (CA1) inhibitor is used in a method for treating or preventing a myeloproliferative disorder, an acute myeloid leukemia (AML) and/or a primary or secondary myelofibrosis. The carbonic Anhydrase 1 is also used as a biomarker for myeloproliferative disorders and other hematopoietic malignancies, and as a biomarker of the efficacy of compounds for treating or preventing these conditions.Type: ApplicationFiled: March 25, 2022Publication date: June 6, 2024Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ PARIS CITÉ, UNIVERSITE PARIS-SACLAYInventors: Paul-Henri ROMEO, Daniel LEWANDOWSKI, Vilma BARROCA, Shohei MURAKAMI
-
Patent number: 12000833Abstract: PI3K signalling is the most increased pathway in human cancers. The four isoforms of PI3K are thought to be activated by different redundant mechanisms leading to a common downstream signalling. However, the mutational pattern of PI3K pathway or its level of expression is not sufficient to predict the sensitivity to PI3K inhibitors. By identifying for the first time a phosphopeptide that predict the sensitivity to p110? and/or p110? inhibitors, the inventors provide insight in how to handle heterogeneity of PI3K expression patterns in tumoral samples for the choice of available PI3K-targetting drugs. Accordingly, the present relates to a phosphopeptide characterized by the amino acid sequence as set forth in SEQ ID NO:1 (PGTPSDHQSQEASQFER) wherein the threonine residue at position 3 is phosphorylated.Type: GrantFiled: November 22, 2018Date of Patent: June 4, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Julie Guillermet-Guibert, Thibaut Douche, Emmanuelle Mouton-Barbosa, Odile Schiltz, Marie-Pierre Bousquet, Célia Cintas
-
Publication number: 20240173424Abstract: The present invention relates to an antibody -drug conjugate comprising a monoclonal antibody or an antigen-binding fragment thereof wherein the monoclonal antibody or the antigen-binding fragment thereof binds to Nectin-4 and wherein the drug is a topoisomerase I inhibitor, particularly exatecan.Type: ApplicationFiled: March 31, 2022Publication date: May 30, 2024Applicants: EMERGENCE THERAPEUTICS AG, UNIVERSITE D’AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE – CNRSInventors: Jack ELANDS, Florence LHOSPPICE, Xavier PRÉVILLE, Daniel OLIVE, Marc LOPEZ
-
Patent number: 11986514Abstract: This invention relates to the treatment of macular edema. Macular edema is the main cause of vision loss during diabetic macular edema, wet AMD (Age Related Macular Degeneration), retinal vein occlusion and chronic intraocular inflammation. Currently, beyond photocoagulation by laser irradiation, two types of drugs are used, protein molecules that neutralize VEGF family members and glucocorticoids, with different mechanisms of action, but targeting one single symptom: macular edema. The inventors have now found that macular edema may be treated by increasing the oncotic pressure of the vitreous. According to the inventors' understanding, causing an increase in the oncotic pressure of the vitreous induces a liquid flow from the interstitial water accumulated in the retina tissue to the vitreous compartment, so as to reduce or stop macular edema.Type: GrantFiled: August 31, 2018Date of Patent: May 21, 2024Assignees: INSERM (INSTITUT NATIONAL DE LASANTE ET DE LA RECHERCHE MEDICALE), SORBONNE UNIVERSITE, UNIVERSITE DE PARIS, ASSISTANCE PUBLIQUE—HOPITAUX DE PARISInventors: Francine Behar-Cohen, Raphael Cohen, Rinath Levy-Boukris, Min Zhao
-
Patent number: 11987631Abstract: The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.Type: GrantFiled: July 31, 2019Date of Patent: May 21, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRSInventors: Alemseged Truneh, Daniel Olive, Christine Pasero, Aude De Gassart